44
Views
65
CrossRef citations to date
0
Altmetric
Article

TAK1-Mediated Serine/Threonine Phosphorylation of Epidermal Growth Factor Receptor via p38/Extracellular Signal-Regulated Kinase: NF-κB-Independent Survival Pathways in Tumor Necrosis Factor Alpha Signaling

, , , , , , & show all
Pages 5529-5539 | Received 24 Mar 2009, Accepted 10 Aug 2009, Published online: 21 Mar 2023

REFERENCES

  • Adachi, S., H. Natsume, J. Yamauchi, R. Matsushima-Nishiwaki, A. K. Joe, H. Moriwaki, and O. Kozawa. 2009. p38 MAP kinase controls EGF receptor downregulation via phosphorylation at Ser1046/1047. Cancer Lett. 277:108–113.
  • Adhikari, A., M. Xu, and Z. J. Chen. 2007. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26:3214–3226.
  • Baud, V., and M. Karin. 2001. Signal transduction by tumor necrosis factor and its relatives. Trends Cell. Biol. 11:372–377.
  • Beg, A. A., and D. Baltimore. 1996. An essential role for NF-κB in preventing TNF-α-induced cell death. Science 274:782–784.
  • Bodmer, J. L., N. Holler, S. Reynard, P. Vinciguerra, P. Schneider, P. Juo, J. Blenis, and J. Tschopp. 2000. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat. Cell Biol. 2:241–243.
  • Choo, M. K., N. Kawasaki, P. Singhirunnusorn, K. Koizumi, S. Sato, S. Akira, I. Saiki, and H. Sakurai. 2006. Blockade of transforming growth factor-β-activated kinase 1 activity enhances TRAIL-induced apoptosis through activation of a caspase cascade. Mol. Cancer Ther. 5:2970–2976.
  • Choo, M. K., H. Sakurai, K. Koizumi, and I. Saiki. 2006. TAK1-mediated stress signaling pathways are essential for TNF-α-promoted pulmonary metastasis of murine colon cancer cells. Int. J. Cancer 118:2758–2764.
  • French, A. R., D. K. Tadaki, and D. A. Lauffenburger. 1995. Intracellular trafficking of epidermal growth factor family ligands is directly influenced by the pH sensitivity of the receptor/ligand interaction. J. Biol. Chem. 270:4334–4340.
  • Galperin, E., and A. Sorkin. 2008. Endosomal targeting of MEK2 requires RAF, MEK kinase activity and clathrin-dependent endocytosis. Traffic 9:1776–1790.
  • Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-κB puzzle. Cell 109:S81–96.
  • Hayden, M. S., and S. Ghosh. 2008. Shared principles in NF-κB signaling. Cell 132:344–362.
  • Kajino-Sakamoto, R., M. Inagaki, E. Lippert, S. Akira, S. Robine, K. Matsumoto, C. Jobin, and J. Ninomiya-Tsuji. 2008. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J. Immunol. 181:1143–1152.
  • Kim, J. W., E. J. Choi, and C. O. Joe. 2000. Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP. Oncogene 19:4491–4499.
  • Kischkel, F. C., D. A. Lawrence, A. Chuntharapai, P. Schow, K. J. Kim, and A. Ashkenazi. 2000. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12:611–620.
  • Kyriakis, J. M., and J. Avruch. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81:807–869.
  • Levkowitz, G., H. Waterman, S. A. Ettenberg, M. Katz, A. Y. Tsygankov, I. Alroy, S. Lavi, K. Iwai, Y. Reiss, A. Ciechanover, S. Lipkowitz, and Y. Yarden. 1999. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol. Cell 4:1029–1040.
  • Li, X., Y. Huang, J. Jiang, and S. J. Frank. 2008. ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling. Cell. Signal. 20:2145–2155.
  • Li, Z. W., W. Chu, Y. Hu, M. Delhase, T. Deerinck, M. Ellisman, R. Johnson, and M. Karin. 1999. The IKKβ subunit of IκB kinase (IKK) is essential for nuclear factor κB activation and prevention of apoptosis. J. Exp. Med. 189:1839–1845.
  • Lynch, T. J., D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman, and D. A. Haber. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129–2139.
  • McElroy, S. J., M. R. Frey, F. Yan, K. L. Edelblum, J. A. Goettel, S. John, and D. B. Polk. 2008. Tumor necrosis factor inhibits ligand-stimulated EGF receptor activation through a TNF receptor 1-dependent mechanism. Am. J. Physiol. 295:G285–G293.
  • Mendelsohn, J., and J. Baselga. 2003. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21:2787–2799.
  • Morandell, S., T. Stasyk, S. Skvortsov, S. Ascher, and L. A. Huber. 2008. Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network. Proteomics 8:4383–4401.
  • Nakakuki, T., N. Yumoto, T. Naka, M. Shirouzu, S. Yokoyama, and M. Hatakeyama. 2008. Analysis of MAPK cascade for kinetic ErbB signaling. PLoS ONE 3:e1782.
  • Ninomiya-Tsuji, J., T. Kajino, K. Ono, T. Ohtomo, M. Matsumoto, M. Shiina, M. Mihara, M. Tsuchiya, and K. Matsumoto. 2003. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J. Biol. Chem. 278:18485–18490.
  • Ninomiya-Tsuji, J., K. Kishimoto, A. Hiyama, J. Inou, Z. Cao, and K. Matsumoto. 1999. The kinase TAK1 can activate the NIK-IκB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398:252–256.
  • Omori, E., K. Matsumoto, H. Sanjo, S. Sato, S. Akira, R. C. Smart, and J. Ninomiya-Tsuji. 2006. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J. Biol. Chem. 281:19610–19617.
  • Paez, J. G., P. A. Jänne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson, and M. Meyerson. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500.
  • Sakon, S., X. Xue, M. Takekawa, T. Sasazuki, T. Okazaki, Y. Kojima, J. H. Piao, H. Yagita, K. Okumura, T. Doi, and H. Nakano. 2003. NF-κB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J. 22:3898–3909.
  • Sakurai, H., H. Miyoshi, W. Toriumi, and T. Sugita. 1999. Functional interactions of transforming growth factor beta-activated kinase 1 with IκB kinases to stimulate NF-κB activation. J. Biol. Chem. 274:10641–10648.
  • Sakurai, H., S. Suzuki, N. Kawasaki, H. Nakano, T. Okazaki, A. Chino, T. T. Doi, and I. Saiki. 2003. Tumor necrosis factor-α-induced IKK phosphorylation of NF-κB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J. Biol. Chem. 278:36916–36923.
  • Sato, S., H. Sanjo, K. Takeda, J. Ninomiya-Tsuji, M. Yamamoto, T. Kawai, K. Matsumoto, O. Takeuchi, and S. Akira. 2005. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat. Immunol. 6:1087–1095.
  • Sayama, K., Y. Hanakawa, H. Nagai, Y. Shirakata, X. Dai, S. Hirakawa, S. Tokumaru, M. Tohyama, L. Yang, S. Sato, A. Shizuo, and K. Hashimoto. 2006. Transforming growth factor-β-activated kinase 1 is essential for differentiation and the prevention of apoptosis in epidermis. J. Biol. Chem. 281:22013–22020.
  • Schneider, M. R., and E. Wolf. 2009. The epidermal growth factor receptor ligands at a glance. J. Cell Physiol. 218:460–466.
  • Sebastian, S., J. Settleman, S. J. Reshki, A. Azzariti, A. Bellizzi, and A. Paradiso. 2006. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim. Biophys. Acta 1766:120–139.
  • Sharma, S. V., D. W. Bell, J. Settleman, and D. A. Haber. 2007. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7:169–181.
  • Shim, J. H., C. Xiao, A. E. Paschal, S. T. Bailey, P. Rao, M. S. Hayden, K. Y. Lee, C. Bussey, M. Steckel, N. Tanaka, G. Yamada, S. Akira, K. Matsumoto, and S. Ghosh. 2005. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19:2668–2681.
  • Shin, M. S., P. Shinghirunnusorn, Y. Sugishima, M. Nishimura, S. Suzuki, K. Koizumi, I. Saiki, and H. Sakurai. 2009. Cross interference with TNF-α-induced TAK1 activation via EGFR-mediated p38 phosphorylation of TAK1-binding protein 1. Biochim. Biophys. Acta 1793:1156–1164.
  • Singh, A. B., and R. C. Harris. 2005. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell. Signal. 17:1183–1193.
  • Singhirunnusorn, P., S. Suzuki, N. Kawasaki, I. I. Saiki, and H. Sakurai. 2005. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-β-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J. Biol. Chem. 280:7359–7368.
  • Singhirunnusorn, P., Y. Ueno, M. Matsuo, S. Suzuki, I. I. Saiki, and H. Sakurai. 2007. Transient suppression of ligand-mediated activation of epidermal growth factor receptor by tumor necrosis factor-α through the TAK1-p38 signaling pathway. J. Biol. Chem. 282:12698–12706.
  • Soldani, C., and A. I. Scovassi. 2002. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 7:321–328.
  • Sorkin, A., and L. K. Goh. 2008. Endocytosis and intracellular trafficking of ErbBs. Exp. Cell Res. 314:3093–3106.
  • Tanoue, T., and E. Nishida. 2003. Molecular recognitions in the MAP kinase cascades. Cell. Signal. 15:455–462.
  • Varfolomeev, E. E., and A. Ashkenazi. 2004. Tumor necrosis factor: an apoptosis JuNKie? Cell 116:491–497.
  • Vergarajauregui, S., A. San Miguel, and R. Puertollano. 2006. Activation of p38 mitogen-activated protein kinase promotes epidermal growth factor receptor internalization. Traffic 7:686–698.
  • Vieira, A. V., C. Lamaze, and S. L. Schmid. 1996. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274:2086–2089.
  • Wan, Y. Y., H. Chi, M. Xie, M. D. Schneider, and R. A. Flavell. 2006. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat. Immunol. 7:851–858.
  • Weihua, Z., R. Tsan, W. C. Huang, Q. Wu, C. H. Chiu, I. J. Fidler, and M. C. Hung. 2008. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13:385–393.
  • Winograd-Katz, S. E., and A. Levitzki. 2006. Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene 25:7381–7390.
  • Yamaoka, T., F. Yan, H. Cao, S. S. Hobbs, R. S. Dise, W. Tong, and D. B. Polk. 2008. Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis. Proc. Natl. Acad. Sci. USA 105:11772–11777.
  • Zhang, H., A. Berezov, Q. Wang, G. Zhang, J. Drebin, R. Murali, and M. I. Greene. 2007. ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Investig. 117:2051–2058.
  • Zhang, X., J. Gureasko, K. Shen, P. A. Cole, and J. Kuriyan. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137–1149.
  • Zwang, Y., and Y. Yarden. 2006. p38 MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J. 25:4195–4206.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.